Stellbrink, H-J <br/><br/>
The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.  [electronic resource] 

 -  HIV medicine  03 2020 
 - 3-16 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1468-1293 
<br/><br/><label>Standard No.: </label>10.1111/hiv.12833  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--adverse effects<br/>Alanine<br/>Anti-HIV Agents--adverse effects<br/>CD4 Lymphocyte Count<br/>Comorbidity<br/>Drug Combinations<br/>Emtricitabine<br/>Equivalence Trials as Topic<br/>HIV Infections--blood<br/>Heterocyclic Compounds, 4 or More Rings--adverse effects<br/>Humans<br/>Piperazines<br/>Pyridones<br/>Risk Factors<br/>Socioeconomic Factors<br/>Tablets<br/>Tenofovir--adverse effects